RxDoctor Payments Data

Rita All

Family · Fort Edward, NYNPI 1003222159

Payments from drug & device makers

$2,391in general payments, 2019–2025

Across 22 payments — averaging $108.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$462
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$250
  • Boston Scientific$219
  • Lilly USA, LLC$204
  • Sanofi-aventis U.S. LLC$183
  • Novo Nordisk$125
  • plus $948 from 9 others

What the payments were for

  • Food & beverage$2,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,391 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$784
Medicare patients
35
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$96,207
JardianceEmpagliflozin82$93,427
OzempicSemaglutide64$80,617
TrulicityDulaglutide56$78,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$58,397
JanuviaSitagliptin Phosphate65$53,029
EliquisApixaban53$48,371
WegovySemaglutide33$45,266
RybelsusSemaglutide25$45,044
MyrbetriqMirabegron50$28,705
Spiriva RespimatTiotropium Bromide22$17,461
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$16,580
Tresiba Flextouch U-200Insulin Degludec11$14,403
SymbicortBudesonide/Formoterol Fumarate27$10,449
LinzessLinaclotide11$8,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$204$174,748134 claims
Novo NordiskOzempic, Wegovy, Rybelsus$125$170,926122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Fort Edward

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →